Heikkinen A M, Niskanen L, Ryynänen M, Komulainen M H, Tuppurainen M T, Parviainen M, Saarikoski S
Department of Obstetrics and Gynecology, University Hospital of Kuopio,
Arterioscler Thromb Vasc Biol. 1999 Feb;19(2):402-7. doi: 10.1161/01.atv.19.2.402.
Postmenopausal hormone replacement therapy (HRT) has favorable effects on the serum lipid profile, and it also decreases the risk of cardiovascular diseases. The apolipoprotein E genotype has influence on serum levels of lipids and lipoproteins; apoE allele epsilon4 (apoE4) is associated with high total and LDL cholesterol levels. Genotype also influences the lipid responses to treatment with diet and statins, but the effect of HRT in different apoE genotypes is unknown. We studied the effects of HRT on the concentrations of serum lipids in apoE4-positive early postmenopausal women (genotypes 3/4 and 4/4) compared with apoE4-negative women (genotypes 2/3 and 3/3) in a population-based, prospective 5-year study. In all, 232 early postmenopausal women were randomized into 2 treatment groups: an HRT group (n=116), which received a sequential combination of 2 mg estradiol valerate (E2Val) from day 1 to 21 and 1 mg cyproterone acetate (CPA) from day 12 to 21 (Climen), and a placebo group (n=116), which received 500 mg/d calcium lactate. Serum concentrations of total, LDL, and HDL cholesterol and triglycerides were measured at baseline and after 2 and 5 years of treatment. A total of 154 women completed the final analysis. During the follow-up period, serum total cholesterol and LDL cholesterol concentrations decreased in the HRT group in apoE4-negative women (8.1% and 17.1%, respectively; P<0.001) but did not change in the HRT group in apoE4-positive women or in the placebo group. Serum HDL cholesterol concentrations decreased in the placebo group (apoE4-negative, 3.9%, P=0.015; apoE4-positive, 8.1%, P=0.004) but did not change significantly in the HRT group. Serum triglyceride levels tended to increase in both study groups and genotypes (15.1% to 36.2%, P<0.038 to 0.001), but no differences were observed between the study groups or genotypes, respectively. Our finding was that in postmenopausal Finnish women LDL cholesterol levels in apoE4-negative subjects respond more favorably to HRT than those in apoE4-positive subjects. This finding has potential importance in postmenopausal women with hypercholesterolemia, if confirmed in other studies.
绝经后激素替代疗法(HRT)对血清脂质谱有有益影响,还能降低心血管疾病风险。载脂蛋白E基因型会影响血脂和脂蛋白的血清水平;载脂蛋白E等位基因ε4(apoE4)与总胆固醇和低密度脂蛋白胆固醇水平升高有关。基因型也会影响饮食和他汀类药物治疗的脂质反应,但HRT在不同apoE基因型中的作用尚不清楚。在一项基于人群的前瞻性5年研究中,我们比较了apoE4阳性的绝经后早期女性(基因型3/4和4/4)与apoE4阴性女性(基因型2/3和3/3)中HRT对血清脂质浓度的影响。总共232名绝经后早期女性被随机分为2个治疗组:HRT组(n = 116),从第1天至21天接受2 mg戊酸雌二醇(E2Val)与从第12天至21天接受1 mg醋酸环丙孕酮(CPA)的序贯联合治疗(Climen),以及安慰剂组(n = 116),接受500 mg/d乳酸钙。在基线以及治疗2年和5年后测量血清总胆固醇、低密度脂蛋白胆固醇、高密度脂蛋白胆固醇和甘油三酯的浓度。共有154名女性完成了最终分析。在随访期间,apoE4阴性女性的HRT组血清总胆固醇和低密度脂蛋白胆固醇浓度降低(分别降低8.1%和17.1%;P < 0.001),但apoE4阳性女性的HRT组或安慰剂组中这些指标没有变化。安慰剂组血清高密度脂蛋白胆固醇浓度降低(apoE4阴性,降低3.9%,P = 0.015;apoE4阳性,降低8.1%,P = 0.004),但HRT组中没有显著变化。两个研究组和基因型中血清甘油三酯水平均有升高趋势(升高15.1%至36.2%,P < 0.038至0.001),但研究组或基因型之间分别未观察到差异。我们的发现是,在绝经后的芬兰女性中,apoE4阴性受试者中的低密度脂蛋白胆固醇水平对HRT的反应比apoE4阳性受试者更有利。如果在其他研究中得到证实,这一发现对绝经后高胆固醇血症女性具有潜在重要意义。